Comparative Pharmacology
Head-to-head clinical analysis: VIGAFYDE versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGAFYDE versus VIGPODER.
VIGAFYDE vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
150 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category C
Category C
Anticonvulsant
Anticonvulsant